Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging.
OBJECTIVE
To compare the mangafodipir trisodium (MnDPDP)-enhanced and ferucarbotran-enhanced magnetic resonance imaging (MRI) for the detection of hepatic metastases.


METHODS
Twenty patients with known hepatic metastasis underwent MR imaging using mangafodipir trisodium and ferucarbotran in at least 1-day intervals. Thirty-eight metastases were confirmed either histologically or clinically. Two radiologists independently reviewed the MnDPDP-enhanced and ferucarbotran-enhanced sets in a random order. The sensitivity and accuracy of lesion detection and the ability to distinguish a benign lesion from a malignant lesion were compared by the areas (Az) under the receiver operating characteristic (ROC) curve. The lesion-liver contrast-to-noise ratios (CNR) were compared by paired t-test.


RESULTS
The overall accuracy for detecting metastases was not significantly different between the MnDPDP set (Az=0.912 and 0.913 for reader 1 and 2, respectively) and the SPIO set (Az=0.920 and 0.950). The CNR at the MnDPDP-enhanced images and the SPIO-enhanced images were not significantly different (P=0.146).


CONCLUSIONS
Both MnDPDP- and ferucarbotran-enhanced MRI have a comparable accuracy in detecting hepatic metastasis.
Choi
Jin-Young
JY
Department of Diagnostic Radiology, Seoul National University Hospital, 28, Yongon-dong, Chongno-gu, Seoul, Republic of Korea.
Kim
Myeong-Jin
MJ
Kim
Joo Hee
JH
Kim
Seung Hyoung
SH
Ko
Heung-Kyu
HK
Lim
Joon Seok
JS
Oh
Young Taik
YT
Chung
Jae-Joon
JJ
Yoo
Hyung Sik
HS
Lee
Jong Tae
JT
Kim
Ki Whang
KW
D000328:Adult; D000368:Aged; D003287:Contrast Media; D003911:Dextrans; D004492:Edetic Acid / Q000031:analogs & derivatives*; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007501:Iron; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D010087:Oxides; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; D007501:Iron; C065507:ferumoxides; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; D052203:Ferrosoferric Oxide